Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Famotidine

FDA-approved product (tablet, oral), marketed as Famotidine, Famotidine Preservative Free, Famotidine Preservative Free (Pharmacy Bulk) and 7 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Famotidine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chest pain
  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Peptic ulcer
  • Rheumatoid arthritis
  • Ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
H2-receptor antagonists
FDA pharmacologic class
Histamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Famotidine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Famotidine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults

    NCT06507904 · start 2026-09-22

    Registered record
    Registry ID
    NCT06507904
    Conditions
    Healthy
    Interventions
    Osivelotor; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-09-22
    Completion
    2027-05-10
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOsivelotor; Famotidine
    PhasePhase 1
    Registry statusNot yet recruiting

  • Paracetamol and Ibuprofen With or Without Famotidine for Calcific Tendinitis of the Shoulder

    NCT07539961 · start 2026-09-01

    Registered record
    Registry ID
    NCT07539961
    Conditions
    Calcific Tendinitis
    Interventions
    Paracetamol + Ibuprofen + Famotidine; Paracetamol + Ibuprofen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCalcific Tendinitis
    InterventionParacetamol + Ibuprofen + Famotidine; Paracetamol + Ibuprofen
    PhaseNot applicable
    Registry statusNot yet recruiting

  • IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life

    NCT07478315 · start 2026-03-15

    Registered record
    Registry ID
    NCT07478315
    Conditions
    Breast Cancer
    Interventions
    withdrawal of the premedication
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-03-15
    Completion
    2026-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionwithdrawal of the premedication
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

    NCT07018635 · start 2025-07-16

    Registered record
    Registry ID
    NCT07018635
    Conditions
    Healthy Participants
    Interventions
    INCB161734; Itraconazole; Rifampin; Esomeprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-07-16
    Completion
    2025-09-29
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionINCB161734; Itraconazole; Rifampin; Esomeprazole +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Prevent Infantile Spasms Relapse

    NCT06819670 · start 2025-05-05

    Registered record
    Registry ID
    NCT06819670
    Conditions
    Infantile Spasms; Infantile Epileptic Spasms Syndrome; West Syndrome
    Interventions
    Prednisolone; Famotidine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfantile Spasms; Infantile Epileptic Spasms Syndrome; West Syndrome
    InterventionPrednisolone; Famotidine; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Novel Strategies for Reducing Burn Scar Itch

    NCT06801626 · start 2025-03-01

    Registered record
    Registry ID
    NCT06801626
    Conditions
    Burn Scar; Itch Scarring; Wound
    Interventions
    Famotidine and 4% topical cromolyn sodium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-01
    Completion
    2027-11-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn Scar; Itch Scarring; Wound
    InterventionFamotidine and 4% topical cromolyn sodium; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

    NCT06766825 · start 2025-02-07

    Registered record
    Registry ID
    NCT06766825
    Conditions
    Post COVID-19 Condition; Long COVID Syndrome; Persistent COVID-19; Persistent COVID Condition; Long COVID
    Interventions
    Plitidepsin 1.5 mg/day; Placebo; Placebo and Plitidepsin 1.5mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-02-07
    Completion
    2026-09-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost COVID-19 Condition; Long COVID Syndrome; Persistent COVID-19; Persistent COVID Condition +1 more
    InterventionPlitidepsin 1.5 mg/day; Placebo; Placebo and Plitidepsin 1.5mg/day
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

    NCT06789172 · start 2025-01-23

    Registered record
    Registry ID
    NCT06789172
    Conditions
    Solid Tumours; Sarcoma; HNSCC; Non Small Cell Lung Cancer; NSCLC; Colorectal Cancer (CRC); Myxofibrosarcoma (MFS); Solitary Fibrous Tumors; Dedifferentiated Liposarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Leiomyosarcoma; Leiomyosarcoma (LMS); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic; Gastric / Gastroesophageal Junction Adenocarcinoma
    Interventions
    OKN4395; Pembrolizumab; Fasting; Fed; H2 Receptor Antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-01-23
    Completion
    2028-09
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumours; Sarcoma; HNSCC; Non Small Cell Lung Cancer +11 more
    InterventionOKN4395; Pembrolizumab; Fasting; Fed +1 more
    PhasePhase 1
    Registry statusRecruiting

  • A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

    NCT06717269 · start 2024-11-30

    Registered record
    Registry ID
    NCT06717269
    Conditions
    Healthy Volunteer
    Interventions
    NX-5948; Esomeprazole; Placebo; Famotidine; Midazolam; Digoxin; Rosuvastatin; Quinidine; NX-5948
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-11-30
    Completion
    2026-05-01
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionNX-5948; Esomeprazole; Placebo; Famotidine +5 more
    PhasePhase 1
    Registry statusCompleted

  • Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors

    NCT06629337 · start 2024-04-01

    Registered record
    Registry ID
    NCT06629337
    Conditions
    Prehypertension (elevated Blood Pressure) or Hypertension
    Interventions
    H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-04-01
    Completion
    2024-08-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrehypertension (elevated Blood Pressure) or Hypertension
    InterventionH1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
    PhaseNot applicable
    Registry statusCompleted

  • PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

    NCT06332638 · start 2024-03-19

    Registered record
    Registry ID
    NCT06332638
    Conditions
    Healthy
    Interventions
    Tegoprazan 12.5mg; Tegoprazan 25mg; Famotidine 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-03-19
    Completion
    2024-07-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTegoprazan 12.5mg; Tegoprazan 25mg; Famotidine 20mg
    PhasePhase 1
    Registry statusUnknown

  • A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

    NCT06207305 · start 2024-01-30

    Registered record
    Registry ID
    NCT06207305
    Conditions
    Metastatic Appendiceal Adenocarcinoma; Intraperitoneal Paclitaxel
    Interventions
    Dexamethasone; Diphenhydramine; Famotidine; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-01-30
    Completion
    2028-01-02
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Appendiceal Adenocarcinoma; Intraperitoneal Paclitaxel
    InterventionDexamethasone; Diphenhydramine; Famotidine; Paclitaxel
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

    NCT06144697 · start 2024-01-29

    Registered record
    Registry ID
    NCT06144697
    Conditions
    Healthy Participants
    Interventions
    BMS-986465; Placebo; Pegasys; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2024-01-29
    Completion
    2024-10-16
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986465; Placebo; Pegasys; Famotidine
    PhasePhase 1
    Registry statusTerminated

  • Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

    NCT06154226 · start 2024-01-10

    Registered record
    Registry ID
    NCT06154226
    Conditions
    Acute Kidney Injury
    Interventions
    Pantoprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-01-10
    Completion
    2024-10-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    InterventionPantoprazole; Famotidine
    PhasePhase 2
    Registry statusCompleted

  • Determinants of Changes in Arterial Load Following Exercise

    NCT05820243 · start 2023-05-12

    Registered record
    Registry ID
    NCT05820243
    Conditions
    Post-Exercise Hypotension
    Interventions
    Moderate Intensity Aerobic Exercise
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-05-12
    Completion
    2024-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Exercise Hypotension
    InterventionModerate Intensity Aerobic Exercise
    PhaseNot applicable
    Registry statusUnknown